Psoriasis Clinical Trial
Official title:
A Study of Topical Indigo Naturalis Treatment in Patients With Mild to Moderate Plaque-type Psoriasis
Psoriasis is a common, chronic skin disease for which only remissive, as opposed to
curative, treatments are available. Traditional Chinese medicine is one of the most
frequently chosen alternative therapies in China and Taiwan, and psoriasis has been treated
for centuries with topical and oral herbal preparations. Topical indigo naturalis ointment
has been reported to exhibit potential anti-psoriatic efficacy. The study objective is to
investigate pharmacological effect and explore targeting mechanisms of Traditional Chinese
Medicine (TCM) Indigo Naturalis topical ointment as a single treatment agent in Chinese
subjects with mild to moderate plaque-type Psoriasis.
This was a single site, randomized, double-blinded, placebo controlled study of topical
indigo naturalis vs. vehicle alone (placebo) to treat mild to moderate plaque-type psoriasis
during an 8-week period. Pharmacological effect will be evaluated by biomarker evaluation
and clinical evaluation. The trial was conducted at the China Medical University Hospital
(CMUH), Taichung, Taiwan. All patients provided written informed consent before inclusion in
the study. The study protocol was approved by the institutional review board (IRB) of CMUH.
Estimated enrollment:
Total of 24 subjects:
mild to moderate psoriasis patients will be randomized into treatment group (n=16) placebo
group (n=8)
Study evaluation:
A baseline and end of the study evaluation on the patients will be performed, including
physical examination, hemogram and blood biochemical analysis (including
glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, and creatinine
measurement). The baseline and end of the study of total body surface area involvement and
Psoriasis Area Severity Index (PASI), PGA, OTPSS scores will be also calculated.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |